Centron receives agency of record assignments for FRAGMIN and GLIADEL Wafer medicines

NewsGuard 100/100 Score

HealthSTAR's Centron, a medical communications company, is pleased to announce that they have been awarded agency of record assignments for FRAGMIN® and GLIADEL® Wafer from Eisai Inc.

FRAGMIN is an anticoagulant that prevents the formation of blood clots. GLIADEL Wafer is used to treat brain tumors.

"We are proud to expand our partnership with Eisai," says Marcia McLaughlin, president of Centron. "FRAGMIN and GLIADEL Wafer are important medicines. We look forward to becoming strategic and creative members of the brand teams."

Source:

HealthSTAR Communications

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.